Codexis and Matrix Laboratories enter into partnership for development and commercialization of novel process

17-Jun-2005

Codexis announced it has signed an agreement with Matrix Laboratories (Matrix), a leading provider of active pharmaceutical ingredients (APIs) to the global pharmaceutical industry, for the development and commercialization of the API for a high-value pharmaceutical product.

Codexis will employ its proprietary pharmaceutical process re-engineering technology platform to develop a novel synthetic process for the product via a Codexis Thoroughbred(TM) biocatalyst. The process will be transferred to Matrix for scale-up and manufacturing. Under the terms of the collaboration, Codexis will receive research and development funding, milestone payments and a royalty on net sales of the product. Matrix will receive exclusive manufacturing and marketing rights to the novel process. Further financial terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!